Payment overview · 2025
General Payments
$32,726.55
59 reported records · 16 companies
Healthcare provider profile · identity verified
Brett Alan Schlifka, D.O.
Allopathic & Osteopathic Physicians|Neurological Surgery · LAKE WORTH, FL · NPI 1790728913
Verified facts
What the public records show
CMS Open Payments records show Brett Alan Schlifka, D.O. received $32,726.55 in general payments during 2025 across 59 reported records.
Spineart USA Inc accounted for 36.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Spineart USA Inc | Unresolved — no canonical attribution shown | $12,040.27 | 36.8% | 11 | 2025 |
| SurGenTec | Unresolved — no canonical attribution shown | $11,000.00 | 33.6% | 3 | 2025 |
| The Institute of Musculoskeletal Science and Education | Unresolved — no canonical attribution shown | $2,910.00 | 8.9% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $2,100.89 | 6.4% | 10 | 2025 |
| Nexxt Spine LLC | Unresolved — no canonical attribution shown | $1,687.93 | 5.2% | 8 | 2025 |
| Intrinsic Therapeutics | Unresolved — no canonical attribution shown | $1,005.00 | 3.1% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$624.23 | 1.9% | 9 | 2025 |
| Kuros Biosciences USA, Inc | Unresolved — no canonical attribution shown | $357.77 | 1.1% | 3 | 2025 |
| Xenix Medical LLC | Unresolved — no canonical attribution shown | $217.44 | 0.7% | 1 | 2025 |
| ulrich medical USA, Inc. | Unresolved — no canonical attribution shown | $208.44 | 0.6% | 2 | 2025 |
| Spinal Elements, INC. | Unresolved — no canonical attribution shown | $142.50 | 0.4% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $140.60 | 0.4% | 1 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $125.00 | 0.4% | 1 | 2025 |
| 4WEB, Inc. | Unresolved — no canonical attribution shown | $95.70 | 0.3% | 1 | 2025 |
| Life Spine, Inc. | Unresolved — no canonical attribution shown | $53.45 | 0.2% | 1 | 2025 |
| Carlsmed, Inc. | Unresolved — no canonical attribution shown | $17.33 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $14,533.85 | 15 |
| Consulting Fee | $11,125.00 | 4 |
| Food and Beverage | $4,157.70 | 39 |
| Royalty or License | $2,910.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Hydroputty Normalized: hydroputty |
Device | SurGenTec | $10,000.00 | 1 | 2025 |
Source payment records
|
|||||
| Alcantara Normalized: alcantara |
Device | The Institute of Musculoskeletal Science and Education | $2,910.00 | 1 | 2025 |
Source payment records
|
|||||
| Spira Normalized: spira |
Device | The Institute of Musculoskeletal Science and Education | $2,910.00 | 1 | 2025 |
Source payment records
|
|||||
| Ti Diagon Normalized: ti diagon |
Device | The Institute of Musculoskeletal Science and Education | $2,910.00 | 1 | 2025 |
Source payment records
|
|||||
| BARRICAID ACD (ANNULAR CLOSURE DEVICE) Normalized: barricaid acd annular closure device |
Device | Intrinsic Therapeutics | $1,005.00 | 5 | 2025 |
Source payment records
|
|||||
| Nexxt Spine Technology Normalized: nexxt spine technology |
Device | Nexxt Spine LLC | $935.29 | 4 | 2025 |
Source payment records
|
|||||
| Ion Navigtion Normalized: ion navigtion |
Device | SurGenTec | $875.00 | 1 | 2025 |
Source payment records
|
|||||
| RISE Normalized: rise |
Device | Globus Medical, Inc. | $360.00 | 2 | 2025 |
Source payment records
|
|||||
| MAGNETOS Normalized: magnetos |
Device | Kuros Biosciences USA, Inc | $357.77 | 3 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $321.73 | 3 | 2025 |
Source payment records
|
|||||
| Matrixx SI Sacral Iliac Fusion Normalized: matrixx si sacral iliac fusion |
Device | Nexxt Spine LLC | $307.59 | 2 | 2025 |
Source payment records
|
|||||
| Nexxt Matrixx SI case discussion Normalized: nexxt matrixx si case discussion |
Device | Nexxt Spine LLC | $263.36 | 1 | 2025 |
Source payment records
|
|||||
| Nexxt Spine Product Review Normalized: nexxt spine product review |
Device | Nexxt Spine LLC | $263.36 | 1 | 2025 |
Source payment records
|
|||||
| RELINE Normalized: reline |
Device | Globus Medical, Inc. | $198.64 | 2 | 2025 |
Source payment records
|
|||||
| Nexxt Spine Product Portfolio Normalized: nexxt spine product portfolio |
Device | Nexxt Spine LLC | $181.69 | 1 | 2025 |
Source payment records
|
|||||
| SI - S2 AI Implants Normalized: si s2 ai implants |
Device | Nexxt Spine LLC | $181.69 | 1 | 2025 |
Source payment records
|
|||||
| SI-LOK Normalized: si lok |
Device | Globus Medical, Inc. | $173.06 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $170.85 | 3 | 2025 |
Source payment records
|
|||||
| Medical Device Normalized: medical device |
Device | Spinal Elements, INC. | $142.50 | 1 | 2025 |
Source payment records
|
|||||
| ALTERA Normalized: altera |
Device | Globus Medical, Inc. | $140.86 | 1 | 2025 |
Source payment records
|
|||||
| ELSA Normalized: elsa |
Device | Globus Medical, Inc. | $137.99 | 1 | 2025 |
Source payment records
|
|||||
| INSTRUMENTS Normalized: instruments |
Device | Globus Medical, Inc. | $137.99 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $131.65 | 3 | 2025 |
Source payment records
|
|||||
| Hydrofiber Normalized: hydrofiber |
Device | SurGenTec | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SABLE Normalized: sable |
Device | Globus Medical, Inc. | $124.07 | 1 | 2025 |
Source payment records
|
|||||
| PERLA TL MIS Normalized: perla tl mis |
Device | Spineart USA Inc | $112.52 | 1 | 2025 |
Source payment records
|
|||||
| SPINE TRUSS SYSTEM Normalized: spine truss system |
Device | 4WEB, Inc. | $95.70 | 1 | 2025 |
Source payment records
|
|||||
| ARx SAI Normalized: arx sai |
Device | Life Spine, Inc. | $53.45 | 1 | 2025 |
Source payment records
|
|||||
| Prolift Lateral Normalized: prolift lateral |
Device | Life Spine, Inc. | $53.45 | 1 | 2025 |
Source payment records
|
|||||
| Simpact Normalized: simpact |
Device | Life Spine, Inc. | $53.45 | 1 | 2025 |
Source payment records
|
|||||
| EXCELSIUS GPS Normalized: excelsius gps |
Device | Globus Medical, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| aprevo Normalized: aprevo |
Device | Carlsmed, Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Celecoxib | Celecoxib | 215 | 99 |
| Gabapentin | Gabapentin | 163 | 75 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 87 |
| Methylprednisolone | Methylprednisolone | 77 | 72 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 51 |
| Pregabalin | Pregabalin | 33 | 14 |
| Methocarbamol | Methocarbamol | 27 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | 12 |
| Meloxicam | Meloxicam | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32,726.55 · 59 records | Spineart USA Inc | ALTERA, ARx SAI, Alcantara, BARRICAID ACD (ANNULAR CLOSURE DEVICE), ELSA, EXCELSIUS GPS, Hydrofiber, Hydroputty, INCEPTIV, INSTRUMENTS, Ion Navigtion, KYPHON EXPRESS II KYPHOPAK TRAY, MAGNETOS, Matrixx SI Sacral Iliac Fusion, Medical Device, Nalu Neurostimulation System, Nexxt Matrixx SI case discussion, Nexxt Spine Product Portfolio, Nexxt Spine Product Review, Nexxt Spine Technology, PERLA TL MIS, Prolift Lateral, RELINE, RISE, SABLE, SI - S2 AI Implants, SI-LOK, SPINE TRUSS SYSTEM, SYNCHROMEDII, Simpact, Spira, Ti Diagon, aprevo | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error